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Cisplatin is one of the most widely used and most potent
chemotherapy drugs. However, side effects in normal tissues
and organs, notably nephrotoxicity in the kidneys, limit the
use of cisplatin and related platinum-based therapeutics.
Recent research has shed significant new lights on the
mechanism of cisplatin nephrotoxicity, especially on the
signaling pathways leading to tubular cell death and
inflammation. Renoprotective approaches are being
discovered, but the protective effects are mostly partial,
suggesting the need for combinatorial strategies.
Importantly, it is unclear whether these approaches would
limit the anticancer effects of cisplatin in tumors.
Examination of tumor-bearing animals and identification of
novel renoprotective strategies that do not diminish the
anticancer efficacy of cisplatin are essential to the
development of clinically applicable interventions.
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Cisplatin is one of the most remarkable successes in ‘the war
on cancer.’ Since the accidental discovery over four decades
ago, cisplatin has been widely used for chemotherapy.1–5 It is
potent, demonstrating one of the highest cure rates, for
example, over 90% in testicular cancers.2–5 Cisplatin and
related platinum-based therapeutics are now being used for
the treatment of testicular, head and neck, ovarian, cervical,
nonsmall cell lung carcinoma, and many other types of
cancer.2–5
Unlike most cancer therapy drugs, which are usually
complex organic compounds, cisplatin is a simple inorganic
molecule. The mechanism of the anticancer activity of
cisplatin is not completely understood, but a widely held
view is that cisplatin binds to DNA, leading to the formation
of inter- and intrastrand cross-links.2,6–10 Cross-linking
results in defective DNA templates and arrest of DNA
synthesis and replication. In rapidly dividing cells, such as
those in cancers, cross-linking can further induce DNA
damage. Mildly damaged DNA can be repaired, whereas
extensive DNA damage leads to irreversible injury and cell
death.
Although cisplatin has been a mainstay for cancer therapy,
its use is mainly limited by two factors: acquired resistance to
cisplatin and severe side effects in normal tissues.2,5 The
molecular mechanism of cisplatin resistance has been studied
extensively, which may involve decreased uptake or increased
efflux of cisplatin, neutralization of cisplatin by glutathione
and other sulfur-containing molecules, increased DNA repair,
and defective apoptotic signaling in response to DNA
damage.5,11–13
The other major limiting factor in the use of cisplatin is
the side effects in normal tissues, which include neurotoxi-
city, ototoxicity, nausea and vomiting, and nephrotoxicity.
For years, various approaches have been attempted to curtail
these side effects. One strategy is to synthesize and screen
for novel cisplatin analogues that have lower toxicity in
normal tissues. In this direction, several cisplatin analogues,
such as carboplatin, have been identified with less severe
side effects.14 Another approach that has been used with
some success is to hydrate the patients during cisplatin
treatment.15,16 Despite these efforts, the side effects of
cisplatin, particularly nephrotoxicity, remain a major factor
that limits the use and efficacy of cisplatin in cancer therapy.
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Understanding the mechanism of cisplatin nephrotoxicity
could lead to novel renoprotective interventions.
CISPLATIN NEPHROTOXICITY
Nephrotoxicity was reported in the initial clinical trials of
cisplatin chemotherapy.17 Now, it is recognized that the
prevalence of cisplatin nephrotoxicity is high, occurring in
about one-third of patient undergoing cisplatin treatment.4,18
Clinically, cisplatin nephrotoxicity is often seen after 10 days
of cisplatin administration and is manifested as lower
glomerular filtration rate, higher serum creatinine, and
reduced serum magnesium and potassium levels.4,19,20 On
the other hand, the long-term effects of cisplatin on renal
function are not completely understood, but it is believed
that cisplatin treatment may lead to subclinical but
permanent reduction in glomerular filtration rate.21 The
pathophysiological basis of cisplatin nephrotoxicity has been
studied for the last three decades. However, only recently has
the research been directed toward the understanding of the
cellular and molecular mechanism. The emerging picture
(Figure 1) is that the exposure of tubular cells to cisplatin
activates complex signaling pathways that lead to tubular cell
injury and death. Meanwhile, a robust inflammatory
response is stimulated, further exacerbating renal tissue
damage. Cisplatin may also induce injury in renal vasculature
and result in decreased blood flow and ischemic injury of the
kidneys, contributing to a decline in glomerular filtration
rate. These events, together, culminate in the loss of renal
function during cisplatin nephrotoxicity, triggering acute
renal failure. Apparently, this is a simplistic view and as
discussed in the following sections, cisplatin nephrotoxicity is
now recognized as a very complex multifactorial process.
CISPLATIN UPTAKE AND METABOLISM
The mechanism of intracellular transport of cisplatin is not
clear and may vary from one cell type to another. Earlier
work using cancer cell lines concluded that about half of
the cisplatin uptake is due to passive diffusion through the
plasma membrane, and the remaining half is mediated by
an unknown transporter.22 In 2002, Ishida et al.23 showed
that deletion of the Ctr1, a high-affinity copper transporter,
results in reduced intracellular accumulation of cisplatin in
yeast, which is associated by increased resistance to cisplatin
toxicity. Similar observations were shown in mouse cell lines
lacking one or both mouse Ctr1 (mCtr1) alleles, suggesting
that copper transporters may mediate cisplatin uptake in
both yeast and mammals. In addition, ATP7B, a copper efflux
transporter, has been shown to be overexpressed in cancer cell
lines that are resistant to cisplatin.24,25 Together, these studies,
mainly from cancer cells, have suggested a critical role for the
copper transport system in cisplatin uptake by cells. It is
interesting to note that Ctr1 is also highly expressed in
proximal tubular cells,26 although the role of these trans-
porters in cisplatin uptake has not been studied in renal
models.
On the other hand, in the renal system, the organic cation
transporters (OCTs) have been implicated in cisplatin
uptake.27,28 OCTs mediate the basolateral-to-apical transport
of several cationic compounds in renal tubular cells. In 2004,
Ludwig et al.27 showed that cisplatin, when applied at the
basolateral side, induced higher toxicity in MDCK cells than
apical side application. The results suggest that cisplatin-
induced tubular cell injury may be related to basolateral
organic cation transport. Notably, cimetidine, an inhibitor of
OCTs, could partially prevent cisplatin-induced cytotoxicity
shown by the decrease of transepithelial electrical resis-
tance.27 Three isoforms of OCTs are expressed in renal
proximal tubules, mainly at the basolateral side.29 Recent
work by Ciarimboli et al.30 provided evidence to suggest that
OCT2 is the critical OCT responsible for cisplatin uptake in
the kidney. They showed that cisplatin uptake was increased
by OCT2 overexpression in HEK293 cells, which was
associated with increased cellular sensitivity to cisplatin
toxicity. Consistently, cimetidine decreased cisplatin uptake
in freshly isolated human proximal tubular cells. In addition,
proximal tubular cells isolated from a human diabetic kidney
showed reduced cisplatin uptake, which was attributed to the
well-documented lower expression of OCT2 in diabetes.
Interestingly, cisplatin did not interact with OCT1. It was
speculated that since OCT1 is mainly expressed in the liver
and OCT2 in the kidneys, this differential expression pattern
of OCTs in different tissues might account for organ-specific
toxicity of cisplatin. Of note, the less nephrotoxic analogues
of cisplatin such as carboplatin and oxaliplatin did not
interact with OCT2.30
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Figure 1 | Overview of the pathophysiological events in cisplatin
nephrotoxicity. Cisplatin enters renal cells by passive and/or
facilitated mechanisms. Exposure of tubular cells to cisplatin activates
signaling pathways that are cell death promoting (MAPK, p53, ROS,
and so on) or cytoprotective (p21). Meanwhile, cisplatin induces TNF-a
production in tubular cells, which triggers a robust inflammatory
response, further contributing to tubular cell injury and death.
Cisplatin may also induce injury in renal vasculature, leading to
ischemic tubular cell death and decreased glomerular filtration rate
(GFR). Together, these pathological events culminate in acute renal
failure.
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After entry into the cell, cisplatin may interact with
various kinds of reactive groups. In the kidney, it has been
suggested that the nephrotoxicity of cisplatin may depend on
metabolic activation, which involves a pathway including
g-glutamyl transpeptidase and cysteine-S-conjugate b-lyase.31
Inhibition of either of the enzymes led to amelioration of
cisplatin nephrotoxicity in mice.32,33 Notably, prostate cancer
xenografts overexpressing g-glutamyl transpeptidase were
more resistant to cisplatin therapy, suggesting that inhibition
of the cisplatin activation pathway may reduce the nephro-
toxicity of cisplatin, yet enhance its antitumor effect.34 Further
investigation is needed to directly test this possibility and
determine whether the bioactivation is indeed critical to
cisplatin nephrotoxicity.
CELL DEATH IN CISPLATIN NEPHROTOXICITY: TYPES AND
LOCATIONS
Renal tissue damage, characterized by tubular cell death, is a
common histopathological feature of cisplatin nephrotoxi-
city. Under this condition, cell death in the form of both
necrosis and apoptosis is identified. Recent studies have
provided new insights into the possible connections between
these two forms of cell death. In addition, the cell types that
undergo apoptosis during cisplatin nephrotoxicity have been
further investigated.
Using cultured renal tubular cells, earlier observations by
Lieberthal et al.35 suggested that the dosage of cisplatin might
determine whether the cells die by necrosis or apoptosis.
Necrotic cell death was observed when a high concentration
of cisplatin (millimolar) was used, while lower concentra-
tions of cisplatin (micromolar) led to apoptosis. Never-
theless, in vivo in animals, both necrosis and apoptosis were
induced in renal tubules following cisplatin administra-
tion.36–38 Is there a relationship between necrosis and
apoptosis in the injured tissues? Necrosis can be induced
directly by severe toxic injury. However, it can also be a
postmortem result of apoptosis, termed secondary necrosis.
In addition, despite their distinct morphologies, necrosis and
apoptosis may share some important signaling events. For
example, mitochondrial damage by proapoptotic proteins
such as Bid and Bax could destine the cells to death. Under
this condition, if downstream apoptotic events are defective
or aborted, the cells will become passive and finally end up
being lysed in the form of necrosis. Although in vivo evidence
to support this scenario is lacking, renoprotective agents
frequently prevent both necrosis and apoptosis in renal
tissues during cisplatin nephrotoxicity.39–41 Moreover, knock-
out of known apoptotic genes such as Bax diminishes tubular
cell apoptosis as well as necrosis under this condition.42
It is well recognized that renal tubules are the major sites
of cell injury and death during cisplatin nephrotoxicity.
Earlier work suggested that the distal tubules were the
primary site of apoptosis.36 However, recent studies indicated
that proximal tubular cells also undergo apoptosis during
cisplatin nephrotoxicity.41,43 Nevertheless, these studies did
not clearly identify the cell type(s) of apoptosis using specific
markers. A more recent study has addressed this question by
using proximal and distal tubule-specific lectins. It was
shown that many apoptotic cells were stained by phytohe-
magglutinin, a proximal tubule-binding lectin, whereas
significantly fewer apoptotic cells were stained by peanut
lectin agglutinin, a distal tubule-binding lectin.42 Thus,
apoptosis occurs in both tubular segments, but the majority
is in proximal tubules. These observations justify the
extensive use of primary as well as immortalized proximal
tubular cells for mechanistic studies of cisplatin nephrotoxi-
city. Interestingly, cisplatin can also induce necrosis and
apoptosis in cultured endothelial cells, although evidence is
yet to be demonstrated for endothelial cell apoptosis during
cisplatin nephrotoxicity in vivo.44
APOPTOTIC PATHWAYS IN CISPLATIN NEPHROTOXICITY
During the last few years, apoptosis of renal tubular cells has
been a focus of mechanistic investigation of cisplatin
nephrotoxicity. Several pathways of apoptosis have been
implicated, including the extrinsic pathway mediated by
death receptors, the intrinsic pathway centered on mitochon-
dria, and the endoplasmic reticulum (ER)-stress pathway
(Figure 2).
In the extrinsic pathway, binding of the death receptors by
ligands at the plasma membrane leads to the recruitment and
activation of caspase-8, which further activate downstream
caspases to induce apoptosis.45 Major death receptors include
Fas, tumor-necrosis factor-a (TNF-a) receptor (TNFR) 1 and
2. In cultured human proximal tubular cells, Razzaque et al.46
showed an upregulation of Fas and Fas ligand by cisplatin,
which was associated with apoptosis. However, definitive
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Figure 2 | Apoptotic pathways activated by cisplatin in renal
tubular cells. Cisplatin activates both intrinsic mitochondrial
pathway (blue) and extrinsic death receptor pathway (green) of
apoptosis. In addition, ER stress may also be induced (gray).
Activation of these pathways leads to caspase-dependent
or -independent apoptosis.
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evidence for a role of Fas in cisplatin-induced tubular cell
apoptosis was not established. On the other hand, Tsuruya
et al.43 demonstrated the amelioration of cisplatin-induced
tubular cell apoptosis and renal failure in TNFR1-deficient
cells and mice, suggesting the involvement of TNFR1
signaling in cisplatin nephrotoxicity. In 2002, Ramesh and
Reeves47 demonstrated an impressive induction of TNF-a by
cisplatin in mice. Importantly, pharmacological and genetic
inhibition of TNF-a attenuated the production of various
cytokines and chemokines, which was accompanied by the
amelioration of cisplatin nephrotoxicity. A follow-up study
by these investigators further showed that TNFR2-deficient,
but not TNFR1-deficient, mice were resistant to cisplatin-
induced renal injury.37 While these studies support a role for
TNF-a in the inflammatory response and cisplatin nephro-
toxicity, it is suggested that TNFR2, and not TNFR1, is
mainly responsible for the pathogenic signaling of TNF-a.37
Of note, TNF-a and its receptors may induce renal injury
primarily by mounting a disastrous inflammatory response
rather than by directly activating the extrinsic pathway of
apoptosis.48
On the other hand, the intrinsic or mitochondrial pathway
has emerged as the major apoptotic pathway in cisplatin
nephrotoxicity. In the intrinsic pathway, cellular stress leads
to the activation of the proapoptotic Bcl-2 family proteins
Bax and Bak, which form porous defects on the outer
membrane of mitochondria, resulting in the release of
apoptogenic factors from the organelles.45,49,50 The apopto-
genic factors released from mitochondria include cytochrome
c, AIF (apoptosis-inducing factor), Smac/DIABLO, endonu-
clease G, and others. Cytochrome c, after being released into
the cytosol, binds to and induces conformational changes in
the adaptor protein Apaf-1, leading to the recruitment and
activation of caspase-9, which in turn after proteolytic
processing activates downstream caspases for caspase-depen-
dent apoptosis. Smac, after being released into cytosol, can
bind and antagonize the caspase inhibitor proteins, IAPs
(inhibitor of apoptosis proteins) to further augment caspase
activation. In contrast, AIF, after being released from
mitochondria, accumulates in the nucleus to induce
apoptosis in a caspase-independent manner. The involvement
of the intrinsic pathway of apoptosis in cisplatin-induced
renal injury was initially suggested by Bax accumulation in
mitochondria and cytochrome c release in cultured kidney
cells.51 Using renal epithelial cells, Lee et al.51 and Park et al.52
provided the first evidence for Bax activation following
cisplatin treatment, which was accompanied by mitochon-
drial release of cytochrome c, activation of caspase-9, and
apoptosis. These initial observations were confirmed by
several other studies using different cell lines.53–56 In
addition, cisplatin induced the release of AIF from mito-
chondria in LLC-PK1 cells.57 Importantly, blockade of Bax by
expressing Bcl-2 diminishes mitochondrial injury and
cisplatin-induced apoptosis.53,54 Moreover, several pharma-
cological agents with demonstrated antiapoptotic effects can
attenuate Bax activation and accumulation in mitochondria,
resulting in prevention of cytochrome c release, inhibition of
caspase activation, and amelioration of apoptosis.53,54,56,58–60
Our recent work has further demonstrated compelling
evidence for tubular apoptosis via the intrinsic pathway
during cisplatin nephrotoxicity using Bax-deficient mouse
models.42 In wild-type (WT) C57BL/6 mice, cisplatin
induced Bax in renal tubular cells, which became active,
accumulated in mitochondria, and was accompanied by
acute kidney injury. Notably, when Bax was genetically
deleted, the animals became resistant to cisplatin. Bax-
deficient mice demonstrated less cytochrome c release and
lower tubular apoptosis. Proximal tubular cells isolated from
these animals were also resistant to cisplatin-induced
apoptosis.42
While a central role for the intrinsic or mitochondrial
pathway of apoptosis in cisplatin nephrotoxicity has been
established, the molecular mechanism underlying mitochon-
drial injury is largely unclear. Specifically, it is unknown how
Bax is activated under the pathological condition. It is
generally believed that Bax activation is related to a shift of
the balance between the pro- and antiapoptotic Bcl-2
proteins to the proapoptotic direction. In cultured tubular
cells, cisplatin treatment leads to the decrease or degradation
of the antiapoptotic proteins including Bcl-2, Bcl-XL, and
Mcl-1,54,61 whereas the proapoptotic proteins such as Bax
and Bak are not changed or even increased. In vivo, the ratio
between Bax and Bcl-2 is elevated during cisplatin nephro-
toxicity.42,62 These changes of apoptotic gene expression are
expected to favor the activation of Bax (and probably Bak as
well) to trigger mitochondrial injury and apoptosis. In
addition, cisplatin treatment can induce the expression of
proapoptotic BH3 domain only proteins. One such example
is PUMA-a (p53-upregulated modulator of apoptosis),
which is induced in a p53-dependent fashion during cisplatin
nephrotoxicity.54 The induced PUMA-a accumulates in
mitochondria, where it interacts with and neutralizes the
antiapoptotic protein Bcl-XL, freeing Bax to form pores on
the outer membrane of mitochondria.54 Moreover, our recent
work has revealed a striking morphological change of
mitochondria during cisplatin injury, from filamentous shape
to punctate fragments.63 Blocking the morphological change
can abrogate mitochondrial injury and prevent cisplatin-
induced apoptosis, suggesting an important role for the
regulation of mitochondrial morphological dynamics in
cisplatin injury.63 How does the morphological change affect
mitochondrial membrane integrity during apoptosis? Does it
contribute to Bax/Bak activation? These are the immediate
questions to be addressed.
In addition to the extrinsic and intrinsic pathways, tubular
cell apoptosis following cisplatin treatment may also involve
the ER-stress pathway. The initiator caspase in the ER
pathway is caspase-12, which is localized at the cytosolic face
of the ER and is activated by ER stress.64 Liu and Baliga65
showed that caspase-12 was activated during cisplatin
treatment of LLC-PK1 cells, and, interestingly, transfection
of an anticaspase-12 antibody attenuated apoptosis in this
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model. The in vitro observations were recently extended to a
rat model of cisplatin nephrotoxicity, where ER stress and
related signaling such as caspase-12 cleavage were demon-
strated.66 Another ER-associated protein that has been
implicated in cisplatin injury is a Ca2þ -independent
phospholipase A2 (ER-iPLA2). Cummings et al.
67 showed
that pharmacological inhibition of ER-iPLA2 led to ameliora-
tion of cisplatin-induced apoptosis in primary rabbit
proximal tubular cultures. ER-iPLA2 may act downstream
of p53 and upstream of caspase-3 in the apoptotic pathway.
Despite these observations, the regulation of ER stress, and,
importantly, its role in cisplatin nephrotoxicity remains to be
established.
Finally, it is important to recognize that although the
classical apoptotic pathways involving caspases play critical
roles in cisplatin nephrotoxicity, not all the apoptosis is
mediated by caspases. In immortalized as well as primary
tubular cells, a significant portion of apoptosis cannot be
inhibited by VAD (carbobenzoxy-valyl-alanyl-aspartyl-
[O-methyl]-fluoromethylketone), a broad-spectrum peptide
inhibitor of caspases.53,68 The mechanism of caspase-
independent apoptosis is currently unclear, but may involve
AIF. In addition, autophagic cell death occurs independent of
caspases.69,70 Whether cisplatin induces autophagy and
whether autophagy is involved in cisplatin-induced cell death
is an interesting area for future investigation.
p21 AND CELL-CYCLE REGULATION IN CISPLATIN
NEPHROTOXICITY
Cell-cycle proteins have emerged as major molecular
regulators of renal cell death and protection during cisplatin
nephrotoxicity.71 Normally, the cell cycle is regulated by
members of the cyclin-dependent kinase (cdk) family and
their specific regulatory proteins called cyclins. Specific cdk/
cyclin complexes regulate major transitions during cell cycle,
such as entry from quiescence, commitment to DNA
synthesis, and finally the transition from G2 to mitosis.
Because of their critical roles, cdks are negatively regulated by
two classes of inhibitors: the INK4 and CIP/KIP family of cdk
inhibitors.72–74
The role of cdks and cdk inhibitors, especially p21, in
cisplatin nephrotoxicity has been demonstrated by Price,
Safirstein, and their colleagues36,75–79 in a series of studies.
Thus, the balance between cdks and p21 is an important
factor, which determines whether the renal tubular cells
survive or undergo cell death (Figure 3). It is clear now that
during cisplatin nephrotoxicity, the quiescent renal cells enter
cell cycle as shown by PCNA (proliferating cell nuclear
antigen) staining and BrdU incorporation in nucleus.36 But
at the same time the expression of p21, a cdk inhibitor of
the CIP/KIP family, is also induced. p21 is induced during
cisplatin nephrotoxicity via p53-dependent as well as
p53-independent mechanisms.75 Notably, p21-null mice are
highly sensitive to cisplatin-induced acute renal failure.36
Compared with WT animals, p21-null mice showed a more
rapid onset of acute renal failure following cisplatin
administration. Consistently, morphological examination of
renal tissues showed severe tissue damage and tubular cell
apoptosis in the p21-null mice. Importantly, these mice
showed higher mortality than their WT littermates. These
observations suggest that p21 induction during cisplatin
nephrotoxicity is a renoprotective response. This inference is
further supported by the cytoprotective effects of p21
overexpression in mouse proximal tubular cells. On the
other hand, pharmacological inhibitors of cell cycle did
not afford general cytoprotective effects, suggesting that p21
per se, rather than the associated cell-cycle inhibition, is the
key to cytoprotection during cisplatin nephrotoxicity.76
The p21 protein has several functional domains, which
can interact with various proteins including cyclin, cdk,
caspase-3, PCNA, and c-Myc, to name a few. Using serial
deletion mutants, Yu et al.77 have recently determined the
critical structural domains in p21 that are responsible for its
cytoprotective action. This analysis narrowed the cytopro-
tective domain down to amino acid 38–91 at the NH2
terminus of p21, which contains the cdk2-binding domain.
Indeed, cdk2 was activated during cisplatin incubation and
the activation was attenuated by p21. Moreover, inhibition of
cdk2 by dominant-negative mutants protected tubular cells
from cisplatin-induced apoptosis.77 These observations
suggest that cdk2 may be an important cell killing molecule
during cisplatin nephrotoxicity and a key target of p21. This
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Figure 3 | p21 and cdk2 in cisplatin-induced kidney injury. p21
is induced and cdk2 is activated during cisplatin treatment. While p21
is cytoprotective, cdk2 promotes tubular cell death. The balance
between p21 and cdk2 is an important determinant of tubular cell
apoptosis and kidney injury during cisplatin nephrotoxicity.
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conclusion is further supported by recent data showing the
protective effects of cdk2 inhibitors in tubular cell cultures
and in vivo in 129/Sv mice.78,79 In addition, cdk2-null mouse
embryonic fibroblasts were shown to be resistant to cisplatin-
induced apoptosis and the sensitivity could be restored by
cdk2 transfection.78,79 Of note, these studies further identi-
fied E2F1 as an important downstream effector of cdk2.79
Together, these observations have demonstrated compelling
evidence for a role of cdk2 in cisplatin nephrotoxicity. p21
may protect renal cells from apoptosis by inhibiting cdk2.
p53 SIGNALING IN CISPLATIN NEPHROTOXICITY
The involvement of p53, the well-recognized tumor suppres-
sor protein, in cisplatin nephrotoxicity was first suggested by
Cummings and Schnellmann.68 It was shown that pifithrin-a,
a pharmacological inhibitor of p53, could partially suppress
cisplatin-induced apoptosis in rabbit proximal tubular
cells.68 We confirmed the inhibitory effects of pifithrin-a
in rat proximal tubular cells and further demonstrated
the inhibitory effects of dominant-negative p53.53 Since
the dominant-negative mutant had a point mutation in
the DNA-binding site of p53, it was suggested that the
proapoptotic action of p53 may be related to its transcrip-
tional activity.53 Consistently, p53 was rapidly phosphory-
lated and induced during cisplatin incubation, prior to
tubular cell apoptosis. The role of p53 in cisplatin
nephrotoxicity is further supported by our recent in vivo
experiments, which showed p53 activation in renal tubular
cells, partially colocalizing with apoptosis. Importantly,
tubular cell apoptosis, renal tissue damage, and cisplatin-
induced renal failure were ameliorated in p53-deficient mice
and by pifithrin-a in WT animals.80
Mechanistically, PUMA-a, a proapoptotic Bcl-2 family
protein, was identified as a major downstream mediator of
the killing action of p53.54 PUMA-a was drastically induced
by cisplatin both in vitro in cultured proximal tubular cells
and in vivo in kidneys, and this induction was dependent on
p53. Upon induction, PUMA-a accumulated in mitochon-
dria, where it interacted with and presumably neutralized
Bcl-XL, freeing Bax to permeabilize the mitochondrial
membrane to release apoptotic factors such as cytochrome
c (Figure 4). Consistently, cisplatin-induced apoptosis was
ameliorated in PUMA-a knockout cells.54 In addition to
PUMA-a, Seth et al.57 suggested that PIDD (p53-induced
protein with death domain) might be another proapoptotic
gene that mediates cisplatin-induced apoptosis downstream
of p53. PIDD was shown to be induced by cisplatin in
primary mouse renal tubular cells in a p53-dependent
manner. Following induction, PIDD might activate caspase-2
to induce AIF release from mitochondria57 (Figure 4). It is
noteworthy that, in addition to gene transcription, p53
may also induce apoptosis by directly activating proapoptotic
Bcl-2 family proteins, leading to mitochondrial injury and the
release of apoptogenic factors.81 Whether the direct mecha-
nism is involved in cisplatin-induced renal tubular cell death is
unknown.
How is p53 activated during cisplatin nephrotoxicity? We do
not have a clear answer yet. Nevertheless, it is generally
believed that p53 activation by cisplatin may be triggered by
DNA damage or genotoxic stress. After entering the cell,
cisplatin is aquated into a highly reactive form (Figure 2),
which can bind to and induce modification of various kinds
of molecules. Among these molecular targets, cisplatin is
believed to cross-link genomic DNA. Cross-linking of DNA
leads to distortion of the duplex structure and stalling of the
replication fork, inducing genotoxic stress. Under this
condition, forced DNA synthesis further leads to single- as
well as double-strand breaks. In cancer cells and tumors,
genotoxic stress and DNA damage are recognized as a major
cellular response to cisplatin and are considered to be a
critical event for its therapeutic effects.2,3,5 In addition, the
activation of DNA repair mechanisms has been implicated in
cisplatin resistance in malignant cells.2,3,5 Research on DNA
DNA damage
by cisplatin
P-p53p53
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PIDDosome
PUMA-α
PUMA-α/BCL-XL
Cytochrome cAIF
Caspase-independent
apotosis
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(caspase-2)
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Figure 4 | p53 signaling cisplatin-induced kidney injury. Cisplatin
induces DNA damage, which activates ATR and results in the
phosphorylation and activation of p53. p53 then induces the
transcription of apoptotic genes including PUMA-a and PIDD. PIDD
activates caspase-2 via the formation of PIDDosome, leading to AIF
release from mitochondria and subsequent caspase-independent
apoptosis. On the other hand, PUMA-a translocates to mitochondria,
and interacts with and neutralizes Bcl-XL. As a result, Bax and
Bak become free to form oligomer pores on the outer membrane
of mitochondria, releasing cytochrome c into the cytosol to
activate caspases via the formation of apoptosome, leading to
caspase-dependent apoptosis.
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damage and repair response during cisplatin nephrotoxicity
is scarce. Nevertheless, a recent study by Zhou et al.82
indicates that proteins related to cell-cycle regulation and
DNA repair, such as cdk inhibitors (p21 and p27), cyclin B1,
cyclin D1, PCNA, GADD 45, and GADD 153, are induced by
cisplatin in kidney cells. In addition, enhanced expression of
DNA repair genes is associated with the amelioration of
cisplatin injury, further suggesting that DNA damage may
contributes to cisplatin nephrotoxicity.82 It remains unclear
as to what is the sensor of cisplatin-induced DNA damage
and which proteins relays the DNA damage signal to p53,
resulting in cell injury and death in kidneys. To gain insights
into this question, our recent work has examined ATM
(ataxia telangiectasia mutated) and ATR (ataxia telangiectasia
and Rad-3-related), two major molecular ‘sensors’ of
genotoxic stress and DNA damage. ATM was shown to be
proteolytically cleaved and inactivated during late stage of
cisplatin treatment in renal tubular cells.83 In sharp contrast,
ATR was activated early following cisplatin exposure and,
notably, suppression of ATR could attenuate cisplatin-
induced p53 activation and apoptosis84 (Figure 4). Further
investigation of DNA damage response in normal and cancer
cells may identify critical differences, which can be targeted
for renoprotection during cisplatin chemotherapy. It is
important to note that although, DNA damage is considered
one of the most important mechanisms of cisplatin-induced
cytotoxicity, targeting of other molecules and structures may
also contribute. For example, cisplatin has been reported to
interact and disrupt the function of Hsp85 contributing to
cisplatin nephrotoxicity.86
MAPK ACTIVATION IN CISPLATIN NEPHROTOXICITY
The MAPK (mitogen-activated protein kinase)-signaling
pathways consist of several tiers of highly conserved serine/
threonine protein kinases, which result in terminal activation
of ERK (extracellular signal-regulated kinase), p38 and JNK
(Jun N-terminal kinase) or SAPK (stress-activated protein
kinase).87,88 Activation of MAPKs regulates cellular home-
ostasis and processes including proliferation, differentiation,
and apoptosis.87,88 ERK, p38, and JNK/SAPK are activated in
various experimental models of cisplatin nephrotoxicity.
However, the roles played by specific MAPKs in cisplatin-
induced renal cell injury appear to be very complicated, vary
between different studies, and may depend on the cell types
and experimental models to be examined.
Of the eight known ERK isoforms, ERK1 and ERK2 are
ubiquitously expressed and most widely studied.87–89 These
two ERKs are activated following phosphorylation by MEK
(MAPK/ERK kinase) 1 and MEK2. In 2002, Nowak90 showed
that ERK1/2 were activated and accumulated in mitochon-
dria during cisplatin treatment of primary cultures of renal
tubular cells. Inhibition of ERK1/2 with PD98059 and U0126,
two pharmacological MEK inhibitors, could ameliorate
cisplatin-induced mitochondrial dysfunction and apoptosis.
Interestingly, PD98059 and U0126 did not prevent cyto-
chrome c release from mitochondria, yet inhibited caspase
activation, suggesting a downstream inhibitory effect. The
cytoprotective effect of PD98059 and U0126 have been
confirmed and extended to immortalized renal tubular cell
lines,91,92 although there is evidence that these inhibitors may
also block upstream apoptotic events including Bax activa-
tion and cytochrome c release.92 Notably, in addition to
pharmacological inhibitors, the latter studies also used
molecular approaches to decipher the role of ERK in
cisplatin nephrotoxicity. It was shown that transient transfec-
tion of constitutively active MEK1 resulted in increased
apoptosis, whereas dominant-negative MEK1 decreased
cisplatin-induced apoptosis in renal tubular cells.92 Impor-
tantly, the study by Arany et al.91 further identified EGFR-
dependent Src kinase activation as a key upstream event for
ERK1/2 activation. In vivo, cisplatin induced an early ERK,
p38, and JNK/SAPK activation, which preceded the devel-
opment of acute renal injury and renal failure.91 A role for
ERK activation in cisplatin nephrotoxicity in vivo was
recently verified by Won et al.93 using U0126.
As compared with ERK, the roles played by p38 and JNK/
SAPK in cisplatin nephrotoxicity are less clear. In immorta-
lized mouse proximal tubule cells, although all three MAPKs
were activated by cisplatin, only ERK was shown to
contribute to apoptosis.91 In contrast to these results, Ramesh
et al.40 demonstrated a role for p38 in cisplatin nephrotoxi-
city using both in vitro and in vivo models. Specifically,
pharmacological inhibitors of p38 (that is, SB203580 and
SKF-86002) were shown to be renoprotective in these
models. These results were confirmed recently by Mishima
et al.94 Interestingly, instead of directly regulating tubular cell
injury and death, p38 may regulate TNF-a expression in
renal tubular cells and consequent inflammatory response
during cisplatin nephrotoxicity.40,94
Jun N-terminal kinase/stress-activated protein kinase
activation by cisplatin was shown in cultured renal tubular
cells as well as kidney tissues.91,95 However, evidence for a
role of JNK/SAPK in cisplatin-induced nephrotoxicity were
not reported until very recently. Using an in vivo rat model,
Francescato et al.95 showed that treatment with the JNK
inhibitor SP600125 could reduce renal apoptosis and
inflammation during cisplatin nephrotoxicity. In light of
the results (sometimes contrasting) reported by different
groups, it is important to analyze ERK, p38, and JNK/SAPK
all together in the same samples and systematically
characterize their temporal and spatial activation during
cisplatin treatment.91 Also, the use of pharmacological
inhibitors should be justified by vigorous examination of
their specificity.
OXIDATIVE STRESS
For over a decade, oxidative stress has been recognized as an
important factor that contributes to cisplatin nephrotoxi-
city.96 Increases of various reactive oxygen species (ROS)
occur during cisplatin treatment of cultured renal tubular
cells, kidney slices, and in vivo in whole animals. Three
mechanisms have been proposed to account for ROS
1000 Kidney International (2008) 73, 994–1007
r e v i e w N Pabla and Z Dong: Cisplatin nephrotoxicity
generation under these pathological conditions. First, once in
a cell, cisplatin is aquated into a highly reactive form, which
can rapidly react with thiol-containing molecules including
glutathinone, a well-recognized cellular antioxidant.4,5
Depletion or inactivation of glutathione and related anti-
oxidants by cisplatin is expected to shift the cellular redox
status, leading to the accumulation of endogenous ROS and
oxidative stress within the cells. Second, cisplatin may induce
mitochondrial dysfunction and increase ROS production via
the disrupted respiratory chain. For example, in porcine
proximal tubular cells, cisplatin treatment for 20 min reduced
the activity of mitochondrial respiration complexes I–IV by
15–55%, resulting in ROS generation.97 Paradoxically, ROS
formation under this situation was dependent on residual
electron flow through the mitochondrial respiratory chain,
because complete inhibition of the respiration complexes
blocked ROS accumulation.97 The role of mitochondrial
production of ROS in cisplatin-induced renal injury was
further indicated by the cytoprotective effects of mitochon-
dria-localized manganese superoxide dismutase.98 Interest-
ingly, in the same study, expression of catalase in
mitochondria did not have significant protective effects,
suggesting that superoxide (and not hydrogen peroxide) may
be the major injurious oxidant species generated by
mitochondria. In contrast, it was shown recently that catalase
and its derivatives not only ameliorate cisplatin-induced
nephrotoxicity but also improve the efficiency of cisplatin to
treat solid tumors.99 Finally, cisplatin may induce ROS
formation in the microsomes via the cytochrome P450 (CYP)
system. Using both in vitro and in vivo models, Baliga and
colleagues38,96,100,101 showed that CYP was an important
source of catalytic iron for ROS generation during cisplatin
treatment. In CYP2E1-null mice, cisplatin-induced ROS
accumulation was attenuated, so was renal injury.38
Despite the recognition of a role for oxidative stress in
cisplatin nephrotoxicity, the critical molecular targets of ROS
in renal tubular cells remain largely unknown. By their broad
reactive nature, ROS may target and modify multiple
molecules in the cells such as lipids, proteins, and DNA,
resulting in cellular stress. Notably, ROS appear to be
involved in the activation of several important signaling
pathways during cisplatin nephrotoxicity. For example,
Ramesh and Reeves40 showed that p38 activation in renal
tissues following cisplatin treatment was abolished by
dimethylthiourea (DMTU), a hydroxyl radical scavenging
chemical, which was accompanied by the amelioration of
inflammation and renal injury. Consistently, we showed
recently that hydroxyl radicals were rapidly produced during
cisplatin incubation of renal tubular cells.59 DMTU and the
general antioxidant N-acetylcysteine suppressed hydroxyl
radical accumulation, p53 activation, and cisplatin nephro-
toxicity in cultured tubular cells and in vivo in C57BL/6
mice.59 These observations suggest that ROS may be one of
the early signals that are at least partially responsible for the
activation of various signaling pathways to culminate in renal
cell injury and death during cisplatin nephrotoxicity.
In addition to injury, renal cells may also mount a
cytoprotective response under oxidative stress. This is best
illustrated by the investigation of heme oxygenase-1 or
HO-1.102–104 HO-1 is a redox-sensitive microsomal enzyme
that catalyzes the degradation of heme into biliverdin, iron,
and carbon monoxide.105 The early induction and cryopro-
tective role of HO-1 during cisplatin-induced acute kidney
injury was first suggested by Agarwal et al.102 Later studies
showed that the HO-1-deficient mice were significantly more
sensitive to cisplatin-induced renal injury as compared with
their WT littermates.103 Moreover, in an in vitro model,
overexpression of HO-1 significantly ameliorated cisplatin-
induced apoptosis.103 The molecular basis of cryoprotective
effects of HO-1 is not entirely clear. But the mechanisms that
have been postulated are degradation of the prooxidant heme
moiety, generation of antioxidant bilirubin, and generation
of cryoprotectant carbon monoxide.105 Indeed, a recent study
has shown that carbon monoxide can significantly ameliorate
cisplatin-induced renal injury in vitro and in vivo.106 Further
research involving the role of HO-1 and its downstream
products may not only provide the mechanistic under-
standing of cisplatin-induced renal injury, but may also lead
to identification of better renoprotective agents.
In various experimental models, renoprotective effects
have been demonstrated for antioxidants including DMTU,
melatonin, selenium, vitamin E, N-acetylcysteine, and many
others.40,59,107–112 However, whether these antioxidant chemi-
cals are renoprotective in human patients during cisplatin-
based chemotherapy is uncertain. In a clinical trial conducted
in 48 Dutch cancer patients, the test group had a dietary
supplement consisting of vitamin C, vitamin E, and
selenium; no significant differences were shown between
the test and the placebo groups in terms of severity of renal
injury induced by cisplatin.113 In contrast, another study
conducted in 1999 showed that oral supplementation of
vitamin E was effective in decreasing the incidence and
severity of cisplatin-induced peripheral neurotoxicity and
nephrotoxicity.114 Patient compliance and the dosage of
antioxidant supplements may be key determinants of the trial
outcome. Of note, in addition to the tested chemicals,
antioxidant agents extracted from natural products have
attracted recent interest.115–119 Importantly, the natural
product antioxidants may detoxify ROS in kidneys, without
affecting the anticancer efficacy of cisplatin. Although the
active ingredients are not known for all these natural
products but if the renoprotective effects are proven true in
humans, these antioxidants could have potential therapeutic
applications.
INFLAMMATION
Acute kidney injury is associated with a robust inflammatory
response.48,120–122 In the case of cisplatin nephrotoxicity, a
myriad of proinflammatory cytokines and chemokines are
induced. Importantly, inflammation contributes to the
development of renal tissue damage and renal failure under
the pathological condition. This inference was initially
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suggested by Deng et al.,123 who showed that the anti-
inflammatory cytokine IL-10 could ameliorate cisplatin-
induced renal tissue injury and tubular cell death. The role of
the inflammatory response in cisplatin nephrotoxicity has
been further established by studies that target specific
inflammatory factors such as TNF-a, using pharmacological
as well as genetic approaches.37,47,48,124
In the inflammatory response triggered by cisplatin,
TNF-a appears to be a key upstream regulator. Ramesh and
Reeves47 showed that pharmacological inhibitors and
antibodies against TNF-a markedly suppressed the induction
of other cytokines during cisplatin nephrotoxicity. Similar
inhibitory effects were shown in TNF-a-deficient mice.
Importantly, inhibition of TNF-a was associated by the
amelioration of cisplatin nephrotoxicity.47 These observa-
tions have been verified and extended by other studies.125–128
Together, these studies have demonstrated a critical role for
TNF-a in mounting the proinflammatory response during
cisplatin nephrotoxicity and the ensuing kidney injury and
acute renal failure.
How does TNF-a stimulate the inflammatory response
and contribute to cisplatin nephrotoxicity? As a pleiotropic
cytokine, TNF-a may engage the cell surface receptors
TNFR1 and TNFR2 to induce a variety of cellular responses,
ranging from inflammation to cell death. Tsuruya et al.43
showed that, compared with WT, TNFR1-deficient mice and
renal tubular cells were more resistant to cisplatin-induced
injury and apoptosis, suggesting an important role for TNF-
a/TNFR1 signaling in tubular cell apoptosis under the
experimental conditions. In sharp contrast, Ramesh and
Reeves37 demonstrated that TNFR1-deficient mice were as
sensitive to cisplatin injury as the WT; however, TNFR2-
deficient mice were more resistant to cisplatin-induced
tubular cell death and renal injury. Although the cause of
the discrepancy between these two studies is not clear, both
suggested a critical role for TNF-a signaling in cisplatin
nephrotoxicity. Subsequent studies by Reeves and collea-
gues40,125–127 have demonstrated that TNF-a is critical to the
induction of proinflammatory factors and recruitment of
inflammatory cells.
Recent research has gained significant insights into the
mechanism underlying TNF-a induction during cisplatin
nephrotoxicity.128 Particularly, a role for renal tubular cells
has been suggested. First, the latest work by Reeves and
colleagues127 indicates that TNF-a is produced during
cisplatin nephrotoxicity mainly by resident kidney cells, and
not by infiltrating inflammatory cells. In this study, chimeric
mouse models were created, in which bone marrow of
recipient animals was ablated and then reconstituted with
bone marrow derived from WT or TNF knockout donor
mice. It was shown that cisplatin induced TNF-a, inflamma-
tion, and renal injury in WT recipients but not in TNF-
deficient recipients, no matter what bone marrow was
reconstituted. Second, emerging evidence has demonstrated
that cisplatin induces TNF-a production in proximal tubular
cells via gene transcription and mRNA stabilization. Notably,
in the presence of endotoxins, TNF-a induction by cisplatin
is dramatically increased.129 These findings suggest that renal
tubular cells contribute significantly to TNF-a production
during cisplatin nephrotoxicity and related pathological
conditions.
While parenchymal kidney cells have been implicated in
TNF-a production during cisplatin nephrotoxicity, other cells
may have a collaborative or regulatory role. Using chimeric
models, Rabb and colleagues130 demonstrated that the
production of proinflammatory cytokines, including TNF-a,
was attenuated in T-cell-deficient mice, suggesting a role for
T cells in triggering inflammation and TNF-a induction
during cisplatin nephrotoxicity. It would be interesting to
investigate how T cells regulate TNF-a production in renal
cells, particularly proximal tubules. In addition to TNF-a,
other cytokines produced during the inflammatory response
may also contribute to cisplatin nephrotoxicity. Nonetheless,
recent work by Faubel et al.131 did not show a significant role
for IL-1b, IL-18, and IL-6 in cisplatin-induced renal injury.
Whether other cytokines contribute to cisplatin nephrotoxi-
city remains to be determined.
RENOPROTECTIVE STRATEGIES AGAINST CISPLATIN
NEPHROTOXICITY
During the course of investigation of cisplatin nephrotoxicity,
a plethora of pharmacologic, molecular, and genetic
approaches have been identified for renoprotection. As
summarized in Table 1, these approaches can be generally
classified on the basis of their primary targets: (1) Cisplatin
uptake by renal cell. The OCT, hOCT2, is at least partially
responsible for transporting cisplatin into renal tubular cells.
Pharmacological inhibition of hOCT2 has been shown to
have renoprotective effects. However, it is unclear whether
hOCT2 inhibition will limit cisplatin uptake by cancer cells
and reduce the therapeutic effects in tumors. (2) Cisplatin
metabolism and bioactivation. Inhibition of g-glutamyl
transpeptidase and cysteine-S-conjugate b-lyase has been
shown to decrease cisplatin nephrotoxicity, and, notably, may
also potentiate the anticancer effects of cisplatin in tumors.
(3) Cell death pathways. Both in vitro and in vivo studies have
shown that directly blocking cell death pathways can
ameliorate cisplatin-induced renal cell death and nephro-
toxicity. (4) Cell-cycle regulators. p21 is induced during
cisplatin nephrotoxicity and protects renal cells from injury
and death. Recent work has further suggested that cdk2
inhibitors can protect renal tubular cells and kidneys against
cisplatin injury. (5) p53. Pharmacologic, molecular, and
genetic blockade of p53 is renoprotective during cisplatin
treatment of renal tubular cells as well as whole animals. (6)
MAPKs. There is evidence that inhibition of specific MAPKs
can partially protect against cisplatin-induced renal tubular
cell injury and nephrotoxicity. (7) Oxidative stress. A number
of studies conducted in both cell cultures and whole animals
have suggested that antioxidants may be used for renoprotec-
tion against cisplatin injury, although the results from clinical
trials are inconclusive. (8) Inflammation. Overall inhibition
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of the inflammatory response by IL-10 and specific suppres-
sion of TNF-a can protect kidneys during cisplatin
treatment. (9) Others. In addition of the above listed
approaches, renoprotective effects have also been shown for
several pharmacological agents. Particularly, PPAR agonists,
fibrate and rosigilitazone, seem to be very effective in
protection against cisplatin nephrotoxicity.
PERSPECTIVE ON RENOPROTECTIVE STRATEGIES
As shown in Table 1 and discussed above, numerous
approaches have been reported to afford renoprotection
during cisplatin treatment. Yet, most of the tests have been
conducted only in cultured cells, mice, or rats. As a result,
whether these approaches are indeed effective in patients is
unknown. To consider clinical use, several important factors
have to be kept in mind. (1) Cisplatin has multiple targets in
cells and thus blocking a single injurious event may only have
partial protective effects in the kidneys. This is clearly shown
by the studies conducted thus far. No matter whether
inflammation, injury signaling, or cell death pathway is
blocked, the protective effects can vary from marginal to
impressive levels, but rarely complete. The partial effects by
individual approaches suggest that it may be possible and
necessary to use several agents together to achieve a clinically
meaningful outcome. (2) In consideration of the combina-
torial strategies, one has to carefully analyze the specific
Table 1 | Renoprotective approaches tested for cisplatin-induced renal cell injury and nephrotoxicity
Experimental evidence Effects on
cancer
No. Mechanism of action Molecular target Inhibitory approach In vitro In vivo therapy References
1. Decreases cisplatin
uptake by renal cells
Organic cation
transporter
Cimetidine,
corticosterone
MDCK, HEK, FHPTC Mice, rat, dogs Unclear 28,30,132
2. Inhibits cisplatin
metabolism
GGT Acivicin LLC-PK1 Rat, mice Sensitize 32,133,134
CSC (Aminooxy)acetic acid
(AOAA)
LLC-PK1 Mice Unclear 133
GST Ketoprofen Rat Unclear 135
3. Inhibits cell death
pathways
Fas/TNFR1/2 Fas KO, TNFR1/2 KO MPTC, NRK52E Rat, mice Unclear 37,43
Bax/Bak Nutlin-3, Bax KO RPTC Mice Unclear 42,55
Caspases VAD, caspase-1 KO RPTC, TKPTS, LLC-PK1 Mice Unclear 39,53,68
4. Inhibits CDK Cell Cycle Roscovitine,
olomoucine, p21
TKPTS Mice Unclear 36,76
CDK2 Purvalanol, p21 TKPTS Mice Unclear 77,78
5. Inhibits p53 p53 Pifithrin, p53 KO RPTC Mice Unclear 53,68,80
6. Inhibits MAPKs MEK/ERK PD98059, U0126 TKPTS, OK, PRTC Mice Unclear 91–93
P38 SKF-86002, SB203580 PTC Mice Unclear 40,94
JNK/SAPK SP600125 Rat Unclear 95
SRC kinase PP1 TKPTS Unclear 91
EGFR AG-1478 TKPTS Unclear 91
7. Antioxidants General antioxidants N-acetylcysteine,
glutathione
TKPTS, RPTC,
LLC-PK1
Mice, rat, humans Unclear 94,136–138
Hydroxyl radical
scavengers
DMTU TKPTS, RPTC,
LLC-PK1
Mice, rat Unclear 40,59,109,139
Degradation of
hydrogen peroxide
Catalase and its
derivatives
Mice Sensitize 99
Dietary antioxidants Lycopene, vitamin C
or E, xanthorrhizol,
glutamine, capsaicin,
hyperbaric oxygen,
quercetin, gum arabic,
rebamipide
RPTC Mice, rat, humans Unclear 112,115,116,
118,
119,140–144
8. Suppresses
inflammation
TNF-a Salicylate, TNF-a KO RPTC Mice Unclear 47,124
IL-10 IL-10 MPTC Mice, rat Unclear 123
9. Others Nitric oxide L-Arginine Mice, rat Unclear 145,146
PPAR Rosigilitazone, fibrate HK-2, LLC-PK1 Mice Sensitize 41,56,147–149
Tissue cytoprotectors Amifostine Humans, rat No effect 150
Local anesthetics Procaine hydrochloride Mice, rat No effect 151
Growth factors Serum thymic factor LLC-PK1 Rat Unclear 152
cdk, cyclin-dependent kinase; CSC, cysteine-S-conjugate b-lyase; DMTU, dimethylthiourea; EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated kinase;
FHPTC, freshly isolated human proximal tubular cells; GGT, g-glutamyl transpeptidase; HEK293, human embryonic kidney cells; HK-2, human renal tubular cell line; IL-10,
interleukin-10; JNK, Jun N-terminal kinase; KO, knockout; LLC-PK1, porcine renal epithelial cells; MAPK, mitogen-activated protein kinase; MDCK, Madin–Darby canine kidney
epithelial cells; MEK, MAPK/ERK kinase; MPTC, mouse proximal tubular cells; NRK52E, normal rat kidney epithelial cells; OK, opossum kidney epithelial cells; PPAR, peroxisome
proliferator-activated receptor; RPTC, rat proximal tubular cells; SAPK, stress-activated protein kinase; TKPTS, cultured mouse proximal tubule cell; TNF-a, tumor-necrosis
factor-a; TNFR, TNF-a receptor; VAD, carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone.
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targets of individual approaches. The best strategy is to take
advantages of inhibition at different levels. For example, anti-
TNF-a agents that limit inflammation can be used together
with approaches that block tubular cell death per se. In
addition, MAPK inhibitors and cdk2 inhibitors may also be
added to the ‘cocktail’ treatment. Such combinatorial strategy
by simultaneously targeting several injury tiers may sig-
nificantly improve the renoprotective efficacy. (3) When the
focus of renal research is kidney protection, one has to take
into consideration the potential effects of renoprotective
approaches on the anticancer actions of cisplatin in tumors.
After all, cisplatin is a drug for chemotherapy of cancers. If
a renoprotective approach diminishes the cancer therapy
effects of cisplatin, then practically it would not be
immediately useful. Unfortunately, many of the studies
focusing on renoprotection were conducted in kidney cells
or tumor-free animals. Whether the identified agents or
approaches affect cancer therapy effects of cisplatin remains
to be examined in tumor-bearing animals. (4) It is expected
that many of the documented renoprotective approaches may
affect the tumor response to cisplatin. Particularly, inhibition
of cell death signaling and pathways that are common to
normal and cancer cells would reduce the chemotherapy
efficacy of cisplatin in tumors. The use of these approaches
would then depend on kidney-specific delivery. (5) Finally,
an ideal approach of renoprotection is to protect the kidneys
yet enhance the therapeutic effects of cisplatin in cancer cells
and tumors. Development of such approaches would rely on
the identification of the critical differences between normal
kidney cells and malignant cancer cells during cisplatin
treatment.
CONCLUSIONS
Research during the last few years has gained significant
insights into the signaling pathways that are responsible for
cisplatin nephrotoxicity. However, how the various pathways
are integrated to induce a remarkable renal pathology
remains largely unknown. Along with the mechanistic
studies, numerous renoprotective approaches have been
documented; nevertheless, the demonstrated protection is
mostly partial and combinatorial strategies may offer better
protective effects. Importantly, the renoprotective approaches
need to be tested in tumor-bearing animals for their potential
effects on cisplatin-mediated chemotherapy in cancers.
Identification of novel approaches that protect normal tissues
including kidneys, without limiting therapeutic effects in
cancer cells or tumors, would open new avenues to enhance
cisplatin-based cancer therapy.
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